KDM5A and KDM5B histone-demethylases are overexpressed in many cancers and have been involved in drug tolerance. Here, we describe that KDM5A, together with KDM5B, contribute to replication stress (RS) response and tolerance. First, they positively regulate RRM2, the regulatory subunit of Ribonucleotide Reductase. Second, they are required for optimal activation of Chk1, a major player of the intra-S phase checkpoint that protects cells from RS. This role in Chk1 activation is probably direct since KDM5A is enriched at ongoing replication forks and associates with both PCNA and Chk1. Because RRM2 is a major determinant of replication stress tolerance, we developed cells resistant to HU, and show that KDM5A/B proteins are required for both RRM2 overexpression and tolerance to HU, in a manner that is independent of their demethylase activity. Altogether, our results indicate that KDM5A/B are major players of RS management. They also show that drugs targeting the enzymatic activity of KDM5 proteins may not affect all cancer-related consequences of KDM5A/B overexpression.
INTRODUCTION

RESULTS
KDM5A and KDM5B positively regulate RRM2
Because KDM5A is involved in the stable repression of E2F-dependent genes during differentiation and senescence, we asked if KDM5A regulates these genes in proliferative U2OS cells. We also analysed the role of KDM5B, since KDM5B can compensate for the absence of KDM5A on a subset of gene promoters [8, 27] . KDM5B or/and KDM5A were depleted by RNA interference using specific siRNA (siK5A, siK5B), and mRNA expression levels of some E2F genes were quantified 48 hours later. A pool of non-targeting siRNA was used as control (siCtle). CDC6, a bona fide E2F gene, was not affected. Surprisingly however, two other E2F target genes, CCNE1 and RRM2, decreased about two fold only when KDM5A and B were depleted together (Fig1A). Decreased expression of RRM2 was also observed at the protein level, using two distinct set of siRNA targeting KDM5A and KDM5B (Fig1B). However, despite this effect on gene regulation, and particularly the drop in RRM2 at both the mRNA and protein levels, the cell cycle of U2OS cells was not disturbed ( Fig 1C) and cell survival was only slightly decreased ( Fig 1D) .
We next performed ChIP experiments to investigate whether KDM5A is recruited to the promoter of RRM2, which is regulated by KDM5 proteins, and that of CDC6, which is not.
As shown in Fig1E, KDM5A was enriched at the promoter regions of both RRM2 and CDC6, and not at their coding sequences nor at the promoter of a gene inactive in non-muscle cells (MYOG). These results are consistent with genome-wide data showing that KDM5A binds to the promoter of actively transcribed genes but that its loss affects only a subset of genes [28, 29] .
Next, we questioned if the demethylase activity of KDM5A/B is required for regulating RRM2 expression. We made use of CPI-455, a well-described and highly specific inhibitor of KDM5 enzymatic activity [18] . U2OS cells were treated for 2 days once a day with 12.5 µM CPI-455. As expected, this treatment led to an increase in H3K4me3 levels ( Fig 1F) . A slight increase in both KDM5B and RRM2 proteins expression was observed by western-blot, whereas KDM5A expression was unchanged ( Fig 1F) . However, KDM5A, KDM5B and RRM2 expressions were not changed or weakly affected at the mRNA level ( Fig 1G) . Thus, RRM2 expression is dependent on KDM5A/B proteins, but not on their demethylase activity. Accordingly, no change in cell survival could be observed upon CPI-455 treatment ( Fig 1H) .
All together, these data show that KDM5A/B act as a positive regulator of RRM2 probably through direct control of its promoter activity and in a demethylase-independent manner.
KDM5A/B restrains replication stress in response to HU
RRM2 is a subunit of the Ribonucleotide Reductase (RNR), catalyzing the formation of deoxyribonucleotides from ribonucleotides, and is thus involved in the supply of dNTPs during S-phase. Under RNR inhibition, replication forks stall, leading to replicative stress and ultimately collapse to generate double strand breaks (reviewed in [26, 30] . In regard of its effect on RRM2 expression, we looked if depletion of KDM5A/B could trigger endogenous replication stress. As a read-out, we monitored the consequences this stress could have on fragile sites breakage during S-phase. Indeed, fragile sites are regions of the genome hard to replicate, and thus hypersensitive to replication stress. When incompletely replicated, they are found into 53BP1 bodies in the next G1 phase, waiting for the following S phase to be fully replicated [31] [32] [33] . U2OS cells were treated with siRNA against KDM5A/B or a non-targeting siRNA pool as control (siCtle), and allowed to grow for 48 hours. Following a 30 min incubation with EdU, that incorporates into replicating DNA during S-phase, cells were stained for 53BP1, EdU and DNA content using DAPI. Immunofluorescence signals were analyzed using a high content imaging system and quantified using the Columbus software.
As illustrated in Fig S1, plotting EdU labeling versus DAPI stain allowed separating cells that were in G1, S or G2/M and quantifying the number of 53BP1 bodies per nucleus in G1 phase.
As a control, we treated U2OS cells with a low dose of aphidicolin, a condition known to increase 53BP1 bodies in G1 cells. As expected, the number of G1 53BP1 foci increases upon treatment with aphidicolin ( Fig S1) . As shown in Figure 2A , the % of G1 cells with a high number of 53BP1 bodies increased in cells depleted for KDM5A/B compared to siCtle treated cells, whereas the number of cells with no or only one 53BP1 body decreased accordingly.
Thus, depletion of KDM5A and B leads to replication-stress induced DNA damage, that may be due in part to RRM2 down-regulation.
We then investigated whether depletion of KDM5A/B could exacerbate the consequence of induced replication stress. We used Hydroxyurea (HU), a potent inhibitor of RNR, which inhibits DNA replication by triggering an unbalance in the dNTPs pool. We analysed the phosphorylation of H2AX (γ-H2AX), a hallmark of the DNA damage response (DDR). U2OS cells were treated with siRNA against KDM5A/B, allowed to grow for 24 hours, before exposure to 50 µM HU for further 24 hours. Following a 30 min incubation with EdU, that incorporates into replicating DNA during S-phase, cells were stained for γ-H2AX, EdU and DNA content with DAPI. Signals were analyzed using a high content imaging system, and γH2AX spots intensity were quantified in cells in G1, S and G2 phases of the cell cycle. As expected, treatment with HU led to a block in S-phase ( Fig 2B) , and an increase in nuclear γ-H2AX content in S-phase cells nuclei ( Fig 2C-D) . Depletion of KDM5A/B did not change the cell cycle distribution upon HU treatment ( Fig 2B) . Strikingly however, depletion of KDM5A/B further increased the level of γ-H2AX induced by HU in S-phase nuclei compared to control cells ( Fig 2C-D) , accompanied by a decrease in EdU incorporation in S-phase cells ( Fig 2E) . Importantly, these results were reproduced with a distinct set of siRNA targeting KDM5A/B, excluding off-target effects ( Fig S2) . This increase in γ-H2AX coupled to a decrease in DNA synthesis suggests that KDM5A/B protect cells from HU-induced replication stress. To test this possibility, we performed a clonogenic assay. This showed that co-depletion of KDM5A and KDM5B sensitizes cells to HU ( Fig 2F) , pointing to a role of KDM5A/B in managing the response to replication stress. However, because long term treatment with HU are known to induce fork collapse, and subsequent generation of replication-dependent DNA double strand breaks [34, 35] , we could not exclude that the results obtained above reflect the role of KDM5A/B in DNA breaks repair that was recently described [16] . To investigate whether KDM5A/B plays a direct role in the replication stress response besides its function in DSB repair, we looked for γ-H2AX signal intensity in nuclei of cells treated for shorter time with 1 mM HU, conditions known to induce rapid and robust replication stress. At these concentrations of HU, replication is almost stopped and EdU cannot be used to follow the cell cycle distribution. Thus, S-phase cells were sorted out by DAPI stain intensity. As shown in Fig2 G-H, cells depleted for KDM5A/B displayed higher levels of γ-H2AX than control cells.
All together, these results show that endogenous or induced replication stress is enhanced upon depletion of KDM5A/B, suggesting a role of KDM5A/B in protecting the genome from this stress.
KDM5A/B are required for full activation of Chk1 in response to RS
The response to RS mostly relies on the activation of the sensor kinase ATR, which phosphorylates itself on Thr1989 [36, 37] and the effector kinase Chk1 on Ser345 [38] , resulting in its activation. This pathway is quickly activated upon RS, protecting the genome and allowing cells to recover from the stress. The activation of Chk1 by ATR at stalled forks depends on many signalling adapter components such as TopBP1, the rad9-rad1-Hus1 (9-1-1) complex, and Claspin [24, 25, 39] . In order to investigate the consequence of KDM5A/B depletion on replication stress response, we first analysed the expression of the mRNA encoding these proteins by RT-qPCR ( Fig 3A and Sup Fig 3) . ATR, CHK1, HUS1 and CLASPIN mRNA were decreased upon depletion of KDM5A/B, and the other tested genes were unchanged ( Figure 3A and S3 ), which could result in a defect in the ATR-Chk1 pathway. Note however that no reproducible effect could be seen on ATR and Chk1 protein expression in the unchallenged conditions ( Fig 3B-C) , suggesting that the decrease of ATR and Chk1 mRNA levels we detect is probably not functionally important.
We next analysed the effect of KDM5A depletion on Chk1 pathway activation. Upon treatment with 1mM HU, Chk1 was rapidly activated as revealed by its phosphorylation on Ser345 ( Fig 3B) . This phosphorylation was seen as soon as 30 min following treatment and is further enhanced after one hour. Upon depletion of KDM5A/B, Ser345 phosphorylation of Chk1 and thus its activation was strongly affected ( Fig 3B) . Importantly, this was observed using another independent couple of siRNAs directed against KDM5A/B ( Fig S4) . By contrast, knocking-down KDM5A/B did not impede phosphorylation of ATR on Thr1989 reflecting ATR activation, nor phosphorylation of RPA on two distinct sites, one targeted by ATR (S33) and the other by DNA-PK (S4/S8) ( Fig 3C) . On the contrary, phosphorylation of ATR and RPA was slightly induced upon KDM5A/B depletion, as shown above for γH2A.X.
Thus, these data demonstrate that Chk1 activation is defective in KDM5A/B-deficient cells despite efficient phosphorylation of ATR-Thr1989, phosphorylation of H2A.X ( Fig 2C) , and RPA-Ser33 ( Fig 3C) , two other substrates of ATR. Altogether, our results thus indicate that KDM5A/B is specifically required for optimal phosphorylation of Chk1 by ATR.
KDM5A localizes to the fork and interacts with PCNA
We next investigated the mechanism by which KDM5A/B could participate in Chk1 activation. Activation of Chk1 is mediated by its ATR-dependent phosphorylation at stalled replication forks. Interestingly, KDM5C was shown to localize at replication forks and interact with PCNA [40, 41] . We thus envisioned that KDM5A/B could also localize at replication forks in order to regulate Chk1 activation. To test this possibility, we performed iPOND experiments, which allow to analyse the proteins present at on-going replication forks by western blot. Cells were labelled 5 min with EdU, which incorporates at active replication forks and allows their purification. As controls, EdU was either not coupled with biotin (Click -) or EdU-labelled cells were submitted to a thymidine chase in order to compare replication fork versus fork-free chromatin (Fig4A). As shown in Figure 4B , KDM5A and KDM5B were specifically enriched at on-going replication forks when compared to the thymidine chase condition, as was PCNA used as a positive control. Note however that a significant amount of KDM5A and KDM5B persisted following thymidine chase, indicating that they also have a global chromatin distribution in agreement with their role in transcription regulation. Next, we investigated whether KDM5A/B recruitment at forks is modulated by replication stress, by treating cells with 1mM HU following the 5 min EdU labelling. In those conditions, replication is stopped and iPOND allows the isolation of stalled replication forks (30 to 120 min of 1mM HU, Fig4A). As previously described [42] , Rad51 was recruited to stalled forks, whereas PCNA was released ( Fig 4B) . KDM5A and KDM5B behaved as PCNA and were released from the fork upon replication stress, decreasing to the levels observed upon thymidine chase (Fig. 4B ).
Given that KDM5A behaves like PCNA, we investigated whether it could be in contact with PCNA in cells by performing Proximity Ligation Assays (PLA). We observed a strong PLA signal only when the two relevant antibodies were included ( Fig 4C) . Importantly, this signal was preferentially detected in S-phase cells ( Fig. S5A ) and decreased upon knockdown of KDM5A ( Fig. S6A ), indicating that it is specific for KDM5A. Thus, these data indicate that endogenous KDM5A and PCNA interact. We next tested the proximity of KDM5A and Chk1, since KDM5A is important for ATR-mediated phosphorylation of Chk1 (see above).
Moreover, Chk1 is a known partner of PCNA that localizes at fork in unchallenged conditions [43, 44] . We observed a PLA signal only when anti-KDM5A and Chk1 antibodies were mixed (Fig4D), and this signal was enriched in S-phase cells ( Fig S5B) , and decreased upon depletion of either KDM5A or Chk1 ( Fig S6B) . Taken together, these data indicate that in unchallenged conditions KDM5A is recruited to the replication fork in close association with PCNA and Chk1. Moreover, its recruitment is regulated by replication stress, like that of PCNA and Chk1, strongly suggesting that the effect of KDM5A on Chk1 phosphorylation by ATR is direct.
KDM5A/B-mediated up-regulation of RRM2 is crucial for the acquisition of tolerance to replication stress.
KDM5A is a major molecular driver of drug tolerance in cancer cells, allowing the generation of the so-called Drug tolerant persisters (DTPs; [17, 18] . On the other hand, resistance of cells to HU depends on the up-regulation of RRM2, likely to provide enough dNTPS to support repair of replication stress-induced DNA damages [45, 46] . Because our results indicate that KDM5A/B is important for the regulation of RRM2 and for RS-induced checkpoint, we postulated that KDM5A/B could be involved in the tolerance of cells to HU.
To address this question, we generated U2OS cells resistant to HU by growing the cells in 0.25mM or 0.5mM HU until cells acquired resistance to the drug. Both concentrations led primarily to a block of cells in S-phase (data not shown). Cells quickly adapted to the presence of 0.25mM HU and a population of HU resistant cells was obtained after 10 days of treatment and called H25. In the case of 0.5 mM HU, a large proportion of cells died and a population of HU resistant cells was obtained following 1 month, and called H50. Both H25 and H50 showed a marked tolerance to increasing doses of HU, compared to U2OS ( Fig 5A) .
This correlated with a lower activation of Chk1 (perhaps due, at least in part, to a decreased expression of Chk1, Fig. 5B ) in response to 1mM HU in both cell lines compared to parental U2OS ( Fig 5B) . This lower activation is probably required for these cells to escape the S phase checkpoint. As expected, RRM2 was up-regulated several fold at both the mRNA and protein levels in both H25 and H50 cell lines compared to U2OS ( Fig 5C and D) . Although KDM5A mRNA levels were increased in H25 and H50 cells compared to U2OS, protein amounts were largely similar in all cell lines. By contrast, KDM5B was more expressed both at the mRNA and protein levels in H25 and H50 cells compared to U2OS ( Fig. 5C and D) .
Thus, we conclude that the two cell lines we generated as tolerant to replication stress harboured up-regulation of KDM5B and RRM2.
These data are consistent with the possibility that this increase in KDM5B expression could be involved in RS tolerance through the up-regulation of RRM2. Because the two HU tolerant cell lines behaved similarly, we decided to work with the H50 cell line to address this question.
We first looked at the effect of depleting KDM5A and KDM5B on the tolerance of H50 cells to the continuous presence of 0.5 mM HU in the culture medium, and per se replication stress.
Depletion of RRM2 was used as a positive control. Upon 48 hours depletion of KDM5A and KDM5B, the expression of RRM2 was diminished at both the mRNA and protein levels ( Fig   6A and 6B) , similarly to what we observed in U2OS cells. To evaluate the effect on the viability of H50 cells, we counted cells 72 hours following siRNA-mediated depletion of KDM5A/B or RRM2. In both cases, the capacity of cells to grow in the presence of 0.5 mM HU was reduced ( Fig 6C) . We next tested the involvement of KDM5A/B enzymatic activity in this function by treating cells with the KDM5 inhibitor CPI-455 or DMSO. As expected, treatment with CPI-455 led to an increase in H3K4me3 levels ( Fig 6D) . However, as in U2OS cells ( Fig 1F-G) , CPI-455 treatment did not decrease RRM2 expression at the mRNA or protein levels ( Fig 6D-E) . Accordingly, we found no effect on the survival of H50 cells following 72 hours of treatment with CPI-455, even if these cells were cultivated in the continuous presence of 0.5mM HU ( Fig 6F) . Thus, taken together, these data indicate that KDM5A/B expression, but not enzymatic activity, is required for the tolerance of H50 cells to replication stress.
We next tested whether this is due to their positive role on RRM2 expression. Strikingly, maintaining RRM2 expression by co-transfecting an expression vector for RRM2 in cells depleted for KDM5A/B ( Figure 6G ) partially restored the viability defect ( Figure 6H ), confirming that this defect is due, at least in part, to RRM2 down-regulation. All together, these results show that the tolerance of U2OS cells to HU depends on the up-regulation of RRM2, which is the consequence, at least in part, of KDM5A/B proteins overexpression.
DISCUSSION
In this study, we show that KDM5A and KDM5B proteins are involved in the management of replication stress (RS), by regulating the level of RRM2, the regulatory subunit of the ribonucleotide reductase RNR, as well as by modulating the activation of Chk1 in response to RS. We further demonstrate the importance of the KDM5A/B-RRM2 axis in the resistance of cells to Hydroxyurea (HU), a potent replication stress inducer. Noticeably, the demethylaseactivity of KDM5A/B is not required for this regulation and for tolerance of HU-induced replication stress.
KDM5A/B is a positive regulator of RRM2
Our results show that KDM5A/B act as positive regulators of RRM2, the regulatory subunit of the ribonucleotide reductase (RNR). RNR is a tetrameric enzyme formed by the association of two RRM1 large subunits and two RRM2 small subunits. RRM2, but not RRM1, is regulated in a cell cycle dependent manner, by both transcriptional and post-transcriptional mechanisms. First, RRM2 is an E2F-target gene and thus its expression is increased in Sphase, a time when dNTPs levels need to be increased to allow DNA synthesis [30, 47] .
Second, two pathways guide RRM2 to proteasome-mediated degradation: one operating in G2 phase depends on the Cyclin F-Skp2 ubiquitin ligase complex [48] , the other operating in S-phase relies on APC/C Cdh1 [49] . Upon depletion of KDM5A/B, RRM2 expression decreases at both the mRNA and protein levels, indicating that KDM5A/B act primarily as a positive transcriptional regulator of RRM2, although a role on RRM2 stability cannot be excluded.
As an enzyme removing the H3K4me3 mark associated with active transcription, KDM5A is often described as a transcription repressor. Positive roles of KDM5A on gene expression have however been previously described although the precise mechanism is not clear.
KDM5A associated to the MRG15 complex was proposed to favour the elongation step of transcription by demethylating H3K4me3 in the body of some genes, and as such in a reaction requiring its demethylase-activity [11] . Here, we show that KDM5A is mainly found at the promoter of RRM2, but not in the coding sequence and that the demethylase activity is not required, excluding such mechanism. A positive role of KDM5A expression was also observed on the expression of genes required for adipocyte differentiation. In a manner similar to what we describe here with KDM5B, KDM5A protein can be compensated by KDM5C in this process, and is found at promoter of genes that are regulated either positively or negatively by KDM5 proteins. However, by contrast to our study, in this case the demethylase activity of KDM5A is required for both types of regulation [28] .
Interestingly, some examples in which KDM5A regulates gene expression or cellular processes independently on its enzymatic activity have already been described. The mechanism involved remains elusive but probably relies on interactions with regulators of gene expression. KDM5A was for example involved in the positive regulation of mitochondrial genes in drosophila, in a manner that depends on its PHD3 domain but not its demethylase activity. The authors proposed that the PHD3 domain allows the recruitment of KDM5A to chromatin by binding to H3K4me3, and may interact with transcriptional coactivators that remain to be identified [12] . In drosophila, Lid, which is the only expressed KDM5 family member, is crucial for larval growth in a manner that is independent of the JMJc domain carrying demethylase activity [50] .
It is thus conceivable that KDM5A recruits transcriptional co-activators to the RRM2 promoter. Such a coactivator could be Tip60, a histone acetyl transferase contained in the MRG15 complex. Equally possible is the possibility that KDM5A impedes the access to the promoter or the activity towards chromatin of a co-repressor. Clearly, how KDM5A/B positively regulates RRM2, in a demethylase-independent manner merits further investigations.
KDM5A localizes at forks and interacts with PCNA and Chk1
In this manuscript, we also provide data indicating that KDM5A plays a role at replication forks. Few studies described so far a role of KDM5 histone demethylases in the process of replication. KDM5C was shown to associate with PCNA and implicated in the assembly of the pre-replication complex by favouring the binding of CDC45 and formation of the active holo-helicase complex [40, 41] . Another study pointed to its role in the replication of heterochromatin together with Suv39h1 and HP1α, impeding transcription of heterochromatic region and genome instability [51] . Finally, KDM5A was shown to associate with ORC2 at centromeres to sustain genomic stability and prevent DNA-replication [52] . Here, we describe that KDM5A is enriched at active replication forks in close association with PCNA, and is required for full activation of Chk1. This ability to interact with PCNA is shared with KDM5C, shown to contain a PIP box of sequence QCDLCQDWF [40] . Interestingly, this sequence is conserved in KDM5A and likely mediates the binding of KDM5A to PCNA. We show by iPOND experiments that upon exposure to the replication stress inducer HU, KDM5A/B behave like PCNA and are released from the fork. Co-depletion of KDM5A and B leads to the inhibition of Chk1 activation, whereas ATR is properly activated and able to phosphorylate H2AX and RPA. This observation places KDM5A downstream of ATR and upstream of Chk1 in the replication stress pathway.
What could be the mechanism by which KDM5A controls Chk1 activation? It could be mediated through the transcriptional or post-translational regulation of key components of the activation of Chk1 by ATR (see Figure 3 and FigS3). However, given that KDM5A localizes at replication forks in a replication stress-dependent manner, it is tempting to speculate that it plays a direct role in Chk1 activation: For example, the capacity of KDM5A to be in close proximity to PCNA and Chk1 may favour the assembly of the complex required for activating Chk1 at forks, or may participate in Chk1 dynamics at replication forks. Indeed, Chk1 is bound to chromatin in unchallenged condition, and is released from the chromatin upon replication stress [53] . We reproduced this result but no change could be observed upon depletion of KDM5A/B (data not shown), suggesting that KDM5A does not regulate Chk1 binding to chromatin per se, but a step in its activation, which remains to be identified.
KDM5A/B and replication stress tolerance.
KDM5A is involved in the emergence of the so-called Drug tolerant persister cells (DTEPs) in cancer, in a manner that is dependent of its demethylase activity [17, 18] . This property, first described in PC9 cells treated with erlotinib was extended to other cellular models of cancers treated with distinct inhibitors either targeting components of signalling pathways or having a more general cytotoxic effect. In particular, KDM5A up-regulation allows the emergence of cells tolerant to cisplatin, a DNA damaging agent, in a manner dependent of its demethylase activity [18, 54] . Whether such a mechanism is conserved in cells becoming resistant to the replication stress-inducer hydoxyurea (HU) has never been reported. To answer this question, we derived from U2OS cell lines H25 and H50 that tolerate the presence of 0.25 mM and 0.5 mM HU, respectively. In contrast to what is described with cisplatin, we show that KDM5A levels do not change. However, KDM5B is up-regulated at both the mRNA and protein levels in H25 and H50 cells when compared to U2OS. Interestingly, KDM5B overexpression has been associated with chemotherapy resistance in epithelial ovarian cancer [23] , with the development and progression of Glioma [22] , and with the presence of a subpopulation of slow-cycling cells involved in long-term tumor maintenance in melanoma [55] . Thus, either KDM5A or KDM5B could fulfil the same function in cancer development/drug resistance, depending on the cell context. Accordingly, we show that KDM5A and KDM5B act redundantly in the regulation of RRM2, meaning that they can compensate each other. This observation is in line with other studies describing a redundant role of KDM5 family members on gene expression [8, 27, 28] , or the up-regulation of either KDM5A or KDM5B depending on cancer cell types [20] .
Although KDM5A/B are important to regulate Chk1 activation in U2OS cells in response to HU, this does not seems to contribute to the resistance phenotype of H50 cells. Indeed, in these cells, Chk1 activation is compromised despite an increase in the expression levels of KDM5B. This defective Chk1-dependent checkpoint signalling probably allows H25 and H50 cell to proliferate in the presence of a concentration of HU that normally stops U2OS cells in S-phase. We rather found that the KDM5A/B-dependent tolerance of H50 cells probably relies, at least in part, on the other mechanism we describe in our study, i.e. RRM2 expression control. This would fit with our finding that RRM2 is overexpressed in H50 cells and with the widely described function of RRM2 in allowing cells to cope with replicative stress.
Strikingly, although KDM5A/B expression is crucial for HU resistance, we report here that their histone demethylase activity is not required. Indeed, treatment with the KDM5 inhibitor CPI-455 had no effect on HU tolerance. On the contrary, it increases KDM5B and RRM2 in both U2OS and HU tolerant cell lines. This stands in contrast to what has been previously described for tolerance to other drugs [17, 18] . One explanation of this difference could be that previous reports addressed a role of KDM5A in the initiation of drug tolerance and not on its maintenance, which is clearly the step we study using the H50 model. Alternatively, the mechanisms involved may be drug-specific with specific mechanisms taking place to achieve tolerance to replication stress. As previously discussed, KDM5A and KDM5B may recruit to chromatin distinct chromatin regulators and/or inhibit the activity of negative regulators such as HDAC and as such may regulate nuclear events independently of their demethylase activity [15] , [12] . Nevertheless, our study reveals the importance of assessing the requirement of the demethylase activity in KDM5A/B oncogenic functions, which may depend on cell types and cancer stages, as well as on the chemotherapeutic used to treat cancer. Our study also underlines the importance of designing new allosteric inhibitors of KDM5A/B, that impede partners association instead of inhibiting demethylase activity.
MATERIALS AND METHODS
Cell culture
U2OS and HeLa S3 cells were obtained from ATCC and cultured in Dulbecco's modified Eagle's medium (DMEM-5.5g/L glucose) plus 10% FBS. Medium was supplemented with 100U/ml penicillin, 100µg/ml of streptomycin (Gibco) and 1mM of Sodium Pyruvate (only for U2OS). H25 and H50 cells were established from U2OS cell line, by adding Hydroxyurea at a concentration of 0.25 or 0.5 mM in the medium. Cells were maintained in a 37°C incubator with 5% CO2.
Antibodies
The following antibodies were used : anti-KDM5A (D28B10-Cell Signaling), anti-KDM5B Transfection of plasmids was done using the U20S-Avalanche reagent (Cambio), as described by the supplier. The plasmid pCDNA 3 -RRM2 was purchased from Addgene. Empty pCDNA 3 was used as control. For rescue experiments, cells were first electroporated with siRNA and 24 hours later transfected with plasmids. siRNA transfection was done a second time at 48h using the Interferin TM polyplus reagent (Ozyme). Cells were counted at 72 hours.
Cell Viability and clonogenic assay
Cells viability was estimated either using WST assay or by counting the cells with trypan blue. For WST, cells were plated in 96 wells plate. After 24h, cells were incubated with or without HU or CPI455 (12.5µM). After 72h of treatment, WST-1[2-(4-Iodophenyl)-3-(4nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium] was added to the medium at a dilution of 1/10, followed by an incubation at 37°C for 2 hours, before measuring the absorbance at 450nm. Alternatively, viable cells were mixed with Trypan blue and counted using the countess II automated cell counter (Life technologies).
For clonogenic assay, U2OS cells were electroporated with siRNA as described before and seeded at 30 cells/cm2. The day after, they were treated for 24 hours with 50 µM HU or left untreated and then were allowed to grow for 10-15 days more before fixation and coloration with 1% Crystal Violet in H 2 O. 
Western-blotting
High-throughput microscopy
The Operetta automated high-content screening microscope (PerkinElmer) was used for quantification of gH2AX, 53BP1 bodies and/or cell cycle analyses. Cells seeded on 96 wells plate were fixed with 4% of freshly prepared paraformaldehyde and permeabilized with 1%Triton X-100 in PBS. A blocking step was performed with 1%BSA for 30min at room temperature. Cells were then incubated with primary antibodies in PBS-1%BSA overnight at 4°C. After three washes, cells were incubated with secondary antibodies (goat anti-rabbit Alexa 647 and/or donkey anti-mouse Alexa 488) at a 1/1000 dilution in PBS-1%BSA for 2h at room temperature. After three washes, a DAPI staining was performed for 10min. For labelling S-phase, cells were labelled with EdU for 20 min prior to fixation. EdU was revealed using the click-it imaging kit (Thermofisher) following the supplier's instructions.
Antibodies are described in the paragraph "antibodies". Image acquisition with a 20× objective lens was automated to obtain at least 20 fields per well, allowing the visualization of a total of 500-1000 cells (three wells were acquired for each condition). Each picture was analyzed with the integrated Columbus software. Briefly, the DAPI-stained nuclei were tests were applied to confirm whether the hypothesis (that can be seen on the boxplot) that there is a differences between indicators of the two populations (such as mean, median, distribution) can be considered as true with a great confidence or can be due to random effect.
Because data distribution was not normal (normality tested with Shapiro Wilk test), we used a
Wilcoxon test to reject the hypothesis that the two populations medians are the same and thus conclude that there is a significant difference between the two medians if the P value is < 0.05, meaning a confidence of 95%.
iPOND
We isolated proteins on nascent DNA (iPOND) as described previously [56, 57] . Newly 
Proximity Ligation Assay (PLA)
The in situ PLA was performed with DuoLink PLA technology probes and reagents (Sigma-Aldrich). Cells were fixed and processed as described above for immunofluorescence, except that the secondary antibodies were those provided with the PLA kit. Antibodies used are described in the paragraph "antibodies". Revelation was performed according to the supplier' instructions. Images were acquired with a fluorescence microscope (DM500, Leica) coupled to Metamorph and analysed using the Colombus program.
Chromatin Immunoprecipitation
Cells were grown until 80% confluence and cross-linked with 2% formaldehyde for 10min before addition of 0.125M Glycine for 5min. Fixed cells were washed with PBS and harvested by scrapping. Pelleted cells were lysed with the following buffer: Pipes 5mM pH 8, KCl 85mM, NP-40 at 0.5%. The lysis was followed by homogenisation with a Dounce homogeniser. Nuclei were harvested by centrifugation and incubated in a nuclear lysis buffer: .
Figure 2-KDM5A/B protect cells from replication stress.
A-U2OS cells were transfected with with siRNA directed against KDM5A and KDM5B (siK5A+B-1), or a non-targeting siRNA pool as control (siCtle) and stained for 53BP1, EdU 
